SAG
ACAD icon

SageView Advisory Group’s Acadia Pharmaceuticals ACAD Stock Holding History

SageView Advisory Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-160
Closed -$4.27K – 596
2025
Q4 		$4.27K Buy
+160
New +$3.82K ﹤0.01% 2007

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

SageView Advisory Group's ACAD Position: Q1 2026 in Review

SageView Advisory Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 160 shares — an estimated $4.27K sold.

SageView Advisory Group first reported a position in ACAD in Q4 2025 and held it in 1 quarter. The position peaked at $4.27K in Q4 2025. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • SageView Advisory Group reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 160 Acadia Pharmaceuticals shares in Q1 2026, an estimated $4.27K.
  • SageView Advisory Group first reported a position in Acadia Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Acadia Pharmaceuticals position peaked at $4.27K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.